The Role of Pentraxin 3 in the Assessment of Cardiovascular Risk and Disease Activity in Patients with Rheumatoid Arthritis and Spondyloarthritis
Bożena Targońska-Stępniak,Anna Drelich-Zbroja
DOI: https://doi.org/10.2147/jir.s497265
IF: 4.5
2024-11-28
Journal of Inflammation Research
Abstract:Bo&zdotena Targo&nacuteska-St&eogonpniak, 1 Anna Drelich-Zbroja 2 1 Department of Rheumatology and Connective Tissue Diseases, Medical University of Lublin, Lublin, Poland; 2 Department of Interventional Radiology and Neuroradiology, Medical University of Lublin, Lublin, Poland Correspondence: Bo&zdotena Targo&nacuteska-St&eogonpniak, Department of Rheumatology and Connective Tissue Diseases, Medical University of Lublin, Ul. Jaczewskiego 8, 20-059, Lublin, Poland, Tel +48 81 7244788, Email Background: Pentraxin 3 (PTX3) is suggested to be both a marker of inflammation and cardiovascular (CV) risk. Aim: The aim of this study was to identify and compare the role of PTX3 in assessment of disease activity and CV risk, in patients with chronic inflammatory diseases, rheumatoid arthritis (RA), and spondyloarthritis (SpA). Methods: The study group consisted of 235 patients (109 RA, and 126 SpA). The following parameters were assessed: disease activity, traditional CV risk factors, carotid intima media thickness (cIMT), PTX3 plasma concentration. Results: The median (IQR) PTX3 concentration was higher in RA than SpA patients [3.44 (2.56– 4.79) vs 2.51 (1.72– 3.62) ng/mL, p< 0.001]. The mean (SD) cIMT value was higher in RA than SpA patients [0.85 (± 0.21) vs 0.75 (± 0.27) mm, p=0.02]. Atherosclerotic plaques were observed in similar number of patients with RA (31, 28.4%) and SpA (34, 27%) (NS). The PTX3 level was significantly higher in RA patients with moderate/high vs low disease activity, and in patients with presence vs no atherosclerotic plagues. In patients with RA correlations were found between PTX3 and disease activity parameters: C-reactive protein, erythrocyte sedimentation rate, tender joint count, disease activity score in 28 joints, white blood cell count (WBC). In multiple linear regression analysis, significantly positive association was confirmed for PTX3 and WBC. No significant relationships were found in patients with SpA. Conclusion: The results of this study point to the dual role of PTX3 in patients with RA, as a biomarker of disease activity, and as a marker of CV complications risk. Keywords: inflammation, disease activity, pentraxin 3, carotid intima media thickness, rheumatoid arthritis, spondyloarthritis Rheumatoid arthritis (RA) and spondyloarthritis (SpA) are the most common chronic joint and spinal inflammatory diseases in adults. Indeed, both RA and SpA are associated with increased cardiovascular (CV) morbidity and mortality, mainly related to premature atherosclerosis. The higher CV risk cannot be entirely explained by the higher prevalence of traditional CV risk factors, including obesity, diabetes, arterial hypertension, smoking, and dyslipidemia. It has been suggested that in patients with chronic inflammatory diseases the main cause of atherosclerosis is chronic inflammation and immune dysregulation resulting from persistent disease activity. 1–5 Atherosclerosis is considered as a chronic inflammatory process of the arterial wall, which results in formation of atherosclerotic plaques. 6 There is a need to find a good biomarker to estimate CV risk in patients with chronic inflammatory diseases. Pentraxin 3 (PTX3) seems to be a marker of localized vascular damage and inflammation. 6,7 PTX3 is a member of the pentraxin family. The two groups of pentraxins are distinguished, short- and long-chain pentraxins. Short-chain pentraxins include biomarkers useful in clinical practice, C-reactive protein (CRP), serum amyloid P (SAP), which are produced mainly by hepatocytes in response to pro-inflammatory cytokines, primarily interleukin 6 (IL-6) and are considered nonspecific markers of inflammation. Long-chain pentraxins include PTX3, and pentraxin 4, neuronal pentraxin 1, neuronal pentraxin 2. It has been reported that PTX3 plays and important role in infection, inflammation, and innate immunity as a component of the complement system, responsible for the clearance of apoptotic cells and regulation of self-antigen presentation. 6–8 PTX3 is produced locally in the vessel wall, synthesized by cells involved directly in atherosclerosis including endothelial cells, smooth muscle cells, macrophages. PTX3 was observed in atherosclerotic plaques, and associated with myocyte damage in myocardial infarction, and unstable angina. 8 It has been suggested that PTX3 is a more sensitive biomarker of atherosclerotic plaque damage than high sensitive CRP (hsCRP), and could be a useful indicator of acute coronary syndrome (ACS), and predictor of mortality after ACS. 5,6 Moreover PTX3 is produced locally in inflamed tissue, by different cell types including fibroblasts, de -Abstract Truncated-
immunology